Expression and clini cal significance of miR129 in gastric adenocarcinoma
MOU Shibin
MOU Yun
GAO Feng
Abstract:Objective To investigate the expression and clinical significance of microRNA129 ( miR129 ) in gastric tubular adenoma tissues,gastric adenocarcinoma tissues and corresponding para-carcinoma tissues.Methods Fifty-five cases of gastric tubular adenoma, 76 cases of gastric adenocarcinoma and corresponding para-carcinoma tissues that were identified by senior pathology doctors were enrolled in the study.The expression levels of miR-129 were detected by in situ hybrization, and the correlation between miR129 expression and clinicopathological parameters was analyzed.Results The positive expression rate of miR-129 in para-carcinoma gastric mucosa tissues was significantly higher than that in gastric tubular adenoma tissues, moreover, which in gastric tubular adenoma tissues was significantly higher than that in gastric adenocarcinoma tissues ( P <0.05).The positive expression rate in well differentiated gastric cancer tissues was significantly higher than that in moderately differentiated and poorly differentiated tissues ( P <0.05).The positive expression rate of miR-129 in stageⅠcarcinoma tissues was obviously higher than that in stage Ⅲ carcinoma tissues, furthermore, which in carcinoma tissues without lymphonode metastasis was significantly higher than that in carcinoma tissues with lymphonode metastasis ( P <0.05).The positive expression rate of miR-129 in gastric tubular adenoma was significantly higher than that in diffuse type adenocarcinoma ( P <0.05).Conclusion The expression levels of miR129 are down-regulated in gastric adenocarcinoma,which may play a role of anti-oncogene, thus miR-129 may be regarded as a marker for evaluating the prognosis of patients with gastric adenocarcinoma.
Keywords:pathologyadenocarcinomahybridization in situmiR-129anti-oncogene
Publication Date:2015-01-01
Online Publishing Date:2025-08-15(First online date of this platform, not the publication date of the document)
Pages:3( 3058-3060 )
